The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Biotechnology


Subject:  Re: DYAI Date:  6/18/2019  12:44 PM
Author:  2K10 Number:  25121 of 25562

Cosmid -- the pumice part is true -- from the 1980's. They call it the 'Jeans to Genes' story.

Started with pumice for stonewashed jeans (1980's), replaced by enzymes, and that's when they discovered and started developing the C1 platform and transformed the company.

In 2015 they sold rights/assets to the industrial side of the business that uses same/similar approach.

On December 31, 2015 Dyadic sold substantially all the assets of its Industrial Technology business to DuPont’s Industrial Biosciences business for US$75 million in cash. Following completion of the transaction, Dyadic intends to focus exclusively on its biopharmaceutical business. DuPont has granted back to Dyadic co-exclusive rights to the C1 technology for use in human and animal pharmaceutical applications, with exclusive ability to enter into sub-license agreements in that field.

So that's the color of the story. Selling the surer thing (industrial revenues) and working to build new pharma revenues may be why management might be taking hefty salaries.

I have not looked at staff levels but business model does seem built to focus on partnerships and licensing the technology. e.g. recent announced partnership with one of world's largest vaccine companies:

Thanks for giving me some more to look into in terms of leadership, scientific advisors, etc. If I find something of note there I'll report it back to the board.
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us